Skip NavigationSkip to Content
Return Return to Search Results

Monoclonal antibodies against components of the IGF system for cancer treatment

  1. Author:
    Feng, Y.
    Dimitrov, D. S.

  2. Author Address

    Feng, Yang, Dimitrov, Dimiter S.] NCI Frederick, NIH, CCR, Nanobiol Program,Protein Interact Grp, Frederick, MD 21702 USA.
    1. Year: 2008
  2. Journal: Current Opinion in Drug Discovery & Development
    1. 11
    2. 2
    3. Pages: 178-185
  4. Type of Article: Review
  1. Abstract:

    Insulin-like growth factor (IGF)-mediated signaling pathways have long been recognized as important targets for cancer therapy. The development of antibodies against the IGF type I receptor (IGF-IR) started in the early 1980s, although clinical studies of these antibodies were not conducted until more recent years. At least eight different anti-IGF-IR antibodies are currently in clinical trials and are reviewed in this article, each antibody was generated by a different method and has unique features. Information collected from these early clinical trials should be taken into consideration during the design of further studies and future clinical applications, as well as in the improvement of the respective antibodies. The development of antibodies against IGF ligands is also discussed.

    See More

  1. Keywords:

External Sources

  1. PMID: 18283605

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel